A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertaintiesRajshekhar Chakraborty, Shahrukh K. Hashmi, Bipin N. Savani et al.|Cancer|2015Cited by 24
Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myelomaGeorge Mellgard, Rajshekhar Chakraborty, Andrew Eisenberger et al.|HemaSphere|2024Cited by 12
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myelomaBeatrice M. Razzo, Alfred L. Garfall, Rajshekhar Chakraborty et al.|Blood|2025Cited by 6
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelinesCharalampos Charalampous, Rajshekhar Chakraborty, Darshi Shah et al.|Annals of Hematology|2024Cited by 3
High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapyGeorge Mellgard, Rajshekhar Chakraborty, Divaya Bhutani et al.|Bone Marrow Transplantation|2024Cited by 2